ArticleDiscover oncology2026
GFPT2 upregulation predicts poor prognosis and is associated with TGF-β/Smad activation in lung adenocarcinoma.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundGlutamine-fructose-6-phosphate amidotransferase 2 (GFPT2) is a rate-limiting enzyme of the hexosamine biosynthetic pathway, but its protein-level expression and functional relevance in lung adenocarcinoma (LUAD) remain unclear.
methodsGFPT2 protein abundance was evaluated in Clinical Proteomic Tumor Analysis Consortium (CPTAC) LUAD proteomics and validated by Western blotting in paired LUAD and adjacent tissues. The Cancer Genome Atlas Lung Adenocarcinoma (TCGA-LUAD) transcriptomes were analyzed for differential expression and pathway enrichment, with survival assessed by Kaplan-Meier and Cox regression. Stable GFPT2 knockdown/overexpression in A549 cells was used to examine proliferation, migration, invasion, and transforming growth factor-β (TGF-β)/Smad2/3 signaling by Western blotting.
resultsGFPT2 protein was significantly upregulated in LUAD compared with adjacent tissues. TCGA-based analyses showed distinct transcriptional profiles between GFPT2 mRNA-high and GFPT2-low tumors, with enrichment of extracellular matrix organization, cell adhesion, and TGF-β-related signaling. High GFPT2 mRNA expression was associated with poorer overall survival and remained an independent adverse prognostic factor in multivariable Cox models. In A549 cells, GFPT2 overexpression was accompanied by enhanced proliferation, migration, and invasion, whereas GFPT2 knockdown showed the opposite effects. Consistently, GFPT2 upregulation was associated with increased TGF-β1 levels and Smad2/3 phosphorylation, suggesting a positive association with TGF-β/Smad signaling activity.
conclusionGFPT2 is upregulated at the protein level in LUAD and is associates with aggressive cellular phenotypes and unfavorable prognosis. Integrated multi-omics analyses and cell-based experiments support a link between GFPT2 and TGF-β/Smad2/3 pathway activation, indicating GFPT2 as a potential prognostic biomarker and therapeutic target.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.